174 related articles for article (PubMed ID: 35090965)
1. HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer.
Luo F; Lu FT; Cao JX; Ma WJ; Xia ZF; Zhan JH; Zeng KM; Huang Y; Zhao HY; Zhang L
Cancer Lett; 2022 Apr; 531():39-56. PubMed ID: 35090965
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T
Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
6. Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer.
Yang N; Liang Y; Yang P; Ji F
Oncol Rep; 2017 May; 37(5):2611-2619. PubMed ID: 28426124
[TBL] [Abstract][Full Text] [Related]
7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
8. Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1α/VEGF signaling pathway.
Wang LM; Zhang LL; Wang LW; Zhu L; Ma XX
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10363-10369. PubMed ID: 31841190
[TBL] [Abstract][Full Text] [Related]
9. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer.
Salaroglio IC; Belisario DC; Akman M; La Vecchia S; Godel M; Anobile DP; Ortone G; Digiovanni S; Fontana S; Costamagna C; Rubinstein M; Kopecka J; Riganti C
J Exp Clin Cancer Res; 2022 Aug; 41(1):243. PubMed ID: 35953814
[TBL] [Abstract][Full Text] [Related]
11. Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor microenvironments predicts unfavorable survival in esophageal squamous cell carcinoma patients.
Zhang L; Ye SB; Li ZL; Ma G; Chen SP; He J; Liu WL; Xie D; Zeng YX; Li J
Int J Clin Exp Pathol; 2014; 7(7):3887-97. PubMed ID: 25120765
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA circPIP5K1A promotes non-small cell lung cancer proliferation and metastasis through miR-600/HIF-1α regulation.
Chi Y; Luo Q; Song Y; Yang F; Wang Y; Jin M; Zhang D
J Cell Biochem; 2019 Nov; 120(11):19019-19030. PubMed ID: 31241217
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Rab17 promotes cell proliferation and invasion in non-small cell lung cancer through STAT3/HIF-1α/VEGF signaling.
Wang M; Wang W; Ding J; Wang J; Zhang J
Thorac Cancer; 2020 Feb; 11(2):379-388. PubMed ID: 31841274
[TBL] [Abstract][Full Text] [Related]
15. Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
Li Y; Xiao X; Wang H; Zhou Q; Jin Z; Zhang Y; Wang Y; Yue F; Zhou S; Yang J
Eur J Pharmacol; 2021 Oct; 909():174411. PubMed ID: 34390710
[TBL] [Abstract][Full Text] [Related]
16. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
18. [Expression of CD82/KAI1 and HIF-1α in non-small cell lung cancer and their relationship to vasculogenic mimicry].
Wu S; Cheng Z; Yu L; Song W; Tao Y
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):918-25. PubMed ID: 22152691
[TBL] [Abstract][Full Text] [Related]
19. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.
He L; Zhang E; Shi J; Li X; Zhou K; Zhang Q; Le AD; Tang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):713-25. PubMed ID: 23292117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
